IC
EIGR

Ikarian Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ikarian Capital’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,344
Closed -$2.77M – 256
2020
Q3 		$2.77M Buy
+11,344
New +$3.53M 0.2% 95

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ikarian Capital's EIGR Position: Q4 2020 in Review

Ikarian Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 11,344 shares — an estimated $2.77M sold.

Ikarian Capital first reported a position in EIGR in Q3 2020 and held it in 1 quarter. The position peaked at $2.77M in Q3 2020. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

  • Ikarian Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Ikarian Capital sold 11,344 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $2.77M.
  • Ikarian Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2020 and held it in 1 quarter.
  • Ikarian Capital's Eiger BioPharmaceuticals, Inc. position peaked at $2.77M in Q3 2020.
  • 91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.